Short title: Continuous versus bolus intraventricular topotecan in a leptomeningeal 32 medulloblastoma model in mice 33 34 Abbreviations: CSF -cerebrospinal fluid; IP -intraperitoneal; IVT -intraventricular; TPT -35 topotecan 2 36 Abstract 37 Leptomeningeal metastasis remains a difficult clinical challenge. Some success has been 38 achieved by direct administration of therapeutics into the cerebrospinal fluid (CSF) circumventing 39 limitations imposed by the blood brain barrier. Here we investigated continuous infusion versus 40 bolus injection of therapy into the CSF in a preclinical model of human Group 3 medulloblastoma, 41 the molecular subgroup with the highest incidence of leptomeningeal disease. Initial tests of 42 selected Group 3 human medulloblastoma cell lines in culture showed that D283 Med and D425 43 Med were resistant to cytarabine and methotrexate. D283 Med cells were also resistant to 44 topotecan, whereas 1 µM topotecan killed over 99% of D425 Med cells. We therefore introduced 45 D425 Med cells, modified to express firefly luciferase, into the CSF of immunodeficient mice. Mice 46 were then treated with topotecan or saline in five groups: continuous intraventricular (IVT) 47 topotecan via osmotic pump (5.28 µg/day), daily bolus IVT topotecan injections with a similar daily 48 dose (6 µg/day), systemic intraperitoneal injections of a higher daily dose of topotecan (15 49 µg/day), daily IVT pumped saline and daily intraperitoneal injections of saline. Bioluminescence 50 analyses revealed that both IVT topotecan treatments effectively slowed leptomeningeal tumor 51 growth in the brains, although histological analysis showed that they were associated with 52 localized brain necrosis. In the spines, bolus IVT topotecan showed a trend towards slower tumor 53 growth compared to continuous (pump) IVT topotecan, as measured by bioluminescence. Both 54 continuous and bolus topotecan IVT showed similar survival that was longer compared to other 55 groups. Thus, both direct IVT topotecan CSF delivery methods produced better anti-56 medulloblastoma effect compared to systemic therapy at the dosages used here. 57 58
Introduction tumors constitute the most common solid cancer [1] . Leptomeningeal The poor prognosis of leptomeningeal medulloblastoma is partially due to the challenge of 72 delivering drugs effectively into the CSF [7]. These challenges include 1) the blood brain barrier, 73 which prevents achievement of therapeutic CSF levels with systemic use of many drugs unless 74 used at high doses that cause unacceptable systemic toxicity [7] , and 2) direct intrathecal drug 75 delivery via infrequent lumbar punctures that may provide only limited leptomeningeal exposure 76 [8] , especially in view of the rapid CSF turnover (6 h in humans, 2 h in mice), rapid drug clearance 77 and uneven distribution in the CSF [9, 10]. Nevertheless, delivery of drugs directly into the CSF 78 can be an attractive modality due to the greater therapeutic concentrations in CSF that can be 79 achieved with significantly lower systemic exposure and fewer systemic side effects [7] . Thus, it 80 is thought that improved delivery of drugs to the CSF will be beneficial.
82
A Phase I clinical trial found that continuous intrathecal infusion of topotecan, a topoisomerase I 83 inhibitor, was well tolerated, suggesting that such an approach may help to circumvent some of 84 the challenges in treatment of leptomeningeal disease [11] . A relevant question is whether such 85 delivery is safe and effective and whether the preferred schedule is bolus or continuous. We 86 therefore compared efficacy of topotecan delivered directly into the CSF as daily bolus injection 87 with similarly-delivered topotecan as continuous infusion, using a mouse model of human 88 leptomeningeal Group 3 medulloblastoma. Here we report that continuous and bolus IVT 89 topotecan into mice with leptomeningeal medulloblastoma yielded similar survival advantage, 90 similar improved control of brain leptomeningeal spread and mild advantage in control of spine 91 leptomeningeal disease for the bolus treatment. We also find that both IVT topotecan delivery 92 methods were associated with localized brain necrosis. We discuss possible limitations and 93 approaches to improve the efficacy of topotecan delivery into the CSF. Daily IP topotecan, daily IVT topotecan, or continuous IVT topotecan infusion via pump. 241
Mice were euthanized when they showed clinical symptoms of tumor. Median survival of 242 each group and its number of mice are noted to the right of panel (A). p-values, calculated 243 by log rank, are shown below the survival panels. 244 245 We noticed that bioluminescence of the spines of mice receiving IVT topotecan rose faster than 246 that of their brains, in which bioluminescence remained low (Fig 2A and not shown ), suggesting 247 that tumor in the spine was less responsive to IVT topotecan compared to the brains. This was 248 different than mice treated with IP topotecan and the two saline groups, where tumor progression 249 in each mouse was grossly similar in the spine and the brain. Plotting the ratio of spine to brain 250 radiance confirmed that the increase in tumor load in brains of mice receiving topotecan IVT by 251 either pump or bolus was indeed slower than in their spines, whereas in the other groups both 252 rose similarly, as manifest in a steady ratio of spine-to-brain radiance ( Fig 4A) . Among the 253 topotecan IVT-treated mice, radiance increase in the brain was slower in the bolus IVT group 254 compared to the continuous infusion (pump) IVT group ( Fig 4B) . Spine tumor progression in mice receiving it by pump but did not reach statistical significance ( Fig 4C) . Thus, IVT topotecan was 257 effective against leptomeningeal medulloblastoma in the brain itself, but less so in the spinal cord. Consistent with the bioluminescence imaging, brains of mice receiving topotecan IVT showed 286 very little tumor on H&E, although they had abundant tumor surrounding their spinal cords (Fig 4  and not shown) . Mice receiving IVT topotecan showed varying degrees of inflammation and 288 ventriculitis ( Table 1) .
289 290 291 FFPE sections from each brain: Numbers in the denominator reflect the number of brains 297 from the group that were assessible for necrosis or inflammation. The numerator reflects 298 the number of brains in which necrosis or inflammation was found. Evaluation was by two 299 independent blinded observers. 300 a Brain necrosis and inflammation were only seen in brains with IVT topotecan (bold font).
301
Where necrosis was present, it was in the general region shown in Fig 6. Inflammation  302 and tumor were not specific to this region. In three of the brains of the IVT bolus TPT 303 group, the brains were torn during harvesting such that they were missing the region where 304 necrosis was seen in other IVT TPT mice. It is possible that this tissue loss occurred during 305 removal of the cannulas when preparing the brains for fixation. Therefore, the denominator 306 for evaluation of necrosis in the group of mice receiving IVT topotecan bolus was only 4 307 of the 7 brains. 308
309
Mice receiving topotecan, regardless of route, did not demonstrate overt clinical systemic toxicity, 310 as reflected in their normal behavior, typical feeding and comparable weight gain during the bulk 311 of the experiment. Symptoms requiring euthanasia were those usually attributed to brain tumor-312 associated symptoms (weight loss, lack of grooming, hunched posture) but not symptoms one 313 would anticipate with symptomatic spinal cord metastases such as paralysis or limb weakness.
314
IVT topotecan mice had at least 1 log lower brain bioluminescence and less intracranial tumor in 315 their brain sections compared to non-IVT topotecan mice ( Fig 4B and not shown) . It was therefore 316 surprising that despite the lower tumor load within their brains ( Fig 4B) , these IVT topotecan mice showed only mild survival advantage ( Fig 3A) and their euthanasia was prompted by brain-related brain regions nor in any of the control mice, including mice who received IVT saline via osmotic 321 pump and those who received topotecan intraperitoneally. Fig 4B) and the trend towards improved control in the spines (Fig 4C) of the was due to the route of drug delivery or the higher targeted dose of the IVT delivery. Since survival 401 was similar in the IP saline control group and the IVT pump saline control group, this suggests 402 that absence or presence of IVT catheter did not by itself affect survival. A minor limitation of the 403 study is that the pumps, designed to reliably deliver drug for at least 28 days, were not replaced 404 with new pumps after that time, since by then half the mice had to be euthanized due to tumor.
405
As a result, it is formally possible that the three remaining mice in the pump group (euthanized on 406 days 32, 41 and 43) had less drug delivered toward the end of the experiment.
408
We found that tumor was well suppressed within the brains of both the bolus and pump topotecan 409 IVT groups, compared to the other groups, but less so in the spines. The IVT bolus delivery 410 showed better control of the brain radiance and a trend toward better control of the spine radiance 411 compared to continuous infusion of topotecan into the CSF. As mentioned above, a slightly higher 412 daily dose of topotecan in the bolus group versus the pump group may have played a role in this, 413 as could the higher peak dose of topotecan in the bolus group. xenograft growth in the brains of this leptomeningeal model using either continuous or bolus IVT modes of delivery, but that similar control of tumor growth in the spines will presumably require 423 more effective delivery to this area.
425
The median survival times of the bolus and continuous IVT topotecan groups were similar, and 426 both were significantly longer than the saline groups or the IP topotecan group. Since tumor 427 burden within the brains of the IVT topotecan mice was much lower than in the other groups ( Fig   428  2A , 4B) and we found localized necrosis in similar brain regions in both IVT topotecan groups (Fig   429  6 , Table 1 ), we suspect that direct topotecan toxicity (e.g., brain necrosis) may have contributed 430 to the demise of these mice. Despite the localized area of necrosis in the brain parenchyma, 431 adjoining areas, including the ventricular lining, were unaffected. Relevant to this, convection 432 enhanced delivery of topotecan into pig brain was reported to induce parenchymal damage in the 433 brains as evidenced by magnetic resonance spectroscopy, with their histology showing necrosis 434 along the catheter track [46] . The localized brain necrosis in our mice was only seen in those 435 treated with IVT topotecan (i.e., those with both cannulas and topotecan) and was found in similar 436 brain regions in them. While this suggests possible seeping of drug around the cannula as 437 hypothesized in the pig brains above [46], we cannot rule out that cannulas which inadvertently 438 terminated within the brain parenchyma may have contributed to the toxicity in some of the IVT 439 topotecan mice.
441
In summary, we showed that prolonged delivery of topotecan directly into intraventricular CSF of 442 mice with leptomeningeal D425 medulloblastoma effectively slows leptomeningeal tumor growth 443 within the brain, is less effective in the spine, confers survival advantage on the mice, but is 
